Second Trimester Screening
Second trimester screening for healthier pregnancy
From 14 to 26 weeks of pregnancy, the quadruple marker screening can provide expectant parents with crucial information about maternal and fetal health.
Quadruple marker screening is conducted during the second trimester of the pregnancy is a non-invasive blood test that assesses the levels of Free hCGβ, AFP, uE3 and Inhibin-A in the maternal blood to identify potential risks and abnormalities in the developing fetus.
Revvity Omics' prenatal screening program:
- Follows FMF (UK) guidelines with FMF accredited analyzers for prenatal screening.
- All maternal markers analyzed – free hCGβ, PAPP-A, PlGF, AFP, uE3, Inhibin-A on Revvity's AutoDELFIA® platform, are CE-marked.
- Graphical interpretation of results with Revvity's validated LifeCycle®
- Risk interpretation based on MoMs of Indian population developed by screening more than 6 lakh pregnancies over the years.
Testing options
Biochemical Testing
This testing service has not been cleared or approved by the U.S. Food and Drug Administration. Testing services may not be licensed in accordance with the laws in all countries. The availability of specific test offerings is dependent upon laboratory location. The content on this page is provided for informational purposes only, not as medical advice. It is not intended to substitute the consultation, diagnosis, and/or treatment provided by a qualified licensed physician or other medical professionals.
